Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

The two hormones bind to specific FSH and LH receptors on ovarian cells. This binding activates intracellular pathways that drive follicular maturation, estrogen production, luteinisation and the final ovulatory surge, creating a hormonal environment that enables egg release and improves the chances of successful conception.

The exact dose is individualized and set by the treating reproductive specialist based on the patient’s age, ovarian reserve, previous response to stimulation and the specific assisted‑reproduction protocol. Clinicians calculate the amount required to achieve optimal follicular development while minimizing the risk of ovarian hyperstimulation.

Meriofert Set is intended for use before conception and is not indicated for administration during an established pregnancy. Its safety in breastfeeding has not been established, so the product should only be used under the guidance of a fertility specialist who can assess risks and benefits for each individual.

To place an order, submit an enquiry on the Meriofert Set product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Meriofert Set contains both FSH and LH in a single injectable formulation, similar to other combined gonadotropin preparations. Compared with recombinant single‑component products, it offers the convenience of a dual‑hormone dose but may differ in molecular structure and purity. Clinical choice depends on physician preference, patient response, and cost considerations.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow local pharmacy guidelines for cold‑chain management during transport.

Meriofert Set is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site is typically the abdomen or thigh for subcutaneous delivery, or the gluteal muscle for intramuscular administration, as directed by the prescribing clinician.

The most serious adverse events include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain and fluid accumulation, and the possibility of multiple pregnancy. Allergic reactions, including anaphylaxis, and rare thromboembolic complications have also been reported, requiring prompt medical attention.

Meriofert Set is contraindicated in women who are already pregnant, have known hypersensitivity to gonadotropins, or have uncontrolled thyroid disease, ovarian cysts, or severe ovarian failure. Patients with active malignancy, uncontrolled hypertension, or a history of severe OHSS should also avoid its use unless a specialist determines that benefits outweigh risks.